<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 05 Apr 2021 10:11:24 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>小分子PD-L1抑制剂：再极医药、红日药业、微芯生物、歌礼制药、东阳光、南京圣和</title><link>https://mp.weixin.qq.com/s/tbknVOk0j9S_ZI1PuAGGlg</link><description></description><content:encoded><![CDATA[小分子PD-L1抑制剂：再极医药、红日药业、微芯生物、歌礼制药、东阳光、南京圣和]]></content:encoded><pubDate>Mon, 05 Apr 2021 07:49:45 +0800</pubDate></item><item><title>自身免疫新靶点：趋化素受体ChemR23</title><link>https://mp.weixin.qq.com/s/6g8gfbHdh1FSihnurCZ8Tg</link><description></description><content:encoded><![CDATA[自身免疫新靶点：趋化素受体ChemR23]]></content:encoded><pubDate>Sun, 04 Apr 2021 07:39:17 +0800</pubDate></item><item><title>国内首款：多禧生物申报MUC1 ADC</title><link>https://mp.weixin.qq.com/s/1qD5g-ZJzYcCCyhqM55U0g</link><description></description><content:encoded><![CDATA[国内首款：多禧生物申报MUC1 ADC]]></content:encoded><pubDate>Sat, 03 Apr 2021 07:18:53 +0800</pubDate></item><item><title>创胜集团技术全梳理</title><link>https://mp.weixin.qq.com/s/n8v8TNhsQ3qDTuwz7gyIyA</link><description></description><content:encoded><![CDATA[创胜集团技术全梳理]]></content:encoded><pubDate>Fri, 02 Apr 2021 09:31:45 +0800</pubDate></item><item><title>Science封面：David Baker利用纳米笼组装抗体</title><link>https://mp.weixin.qq.com/s/I6vsdy_ON7o8dKjqxouKIw</link><description></description><content:encoded><![CDATA[Science封面：David Baker利用纳米笼组装抗体]]></content:encoded><pubDate>Fri, 02 Apr 2021 09:31:45 +0800</pubDate></item><item><title>Science：歇会儿再干活，CAR-T更高效</title><link>https://mp.weixin.qq.com/s/K2MK2Y5HQ-lFP6nButEH5A</link><description></description><content:encoded><![CDATA[Science：歇会儿再干活，CAR-T更高效]]></content:encoded><pubDate>Fri, 02 Apr 2021 09:31:45 +0800</pubDate></item><item><title>中国生物医药行业的研发竞争</title><link>https://mp.weixin.qq.com/s/w2KxP9COVah5Wj41j1_yZg</link><description></description><content:encoded><![CDATA[中国生物医药行业的研发竞争]]></content:encoded><pubDate>Thu, 01 Apr 2021 09:23:33 +0800</pubDate></item><item><title>君实生物申报CTLA-4抗体</title><link>https://mp.weixin.qq.com/s/AdodJTo8oTqbaNJbko90lg</link><description></description><content:encoded><![CDATA[君实生物申报CTLA-4抗体]]></content:encoded><pubDate>Thu, 01 Apr 2021 09:23:33 +0800</pubDate></item><item><title>肿瘤免疫新靶点：PLA2</title><link>https://mp.weixin.qq.com/s/2nMXE0IR1FnFaNWjlkV0dg</link><description></description><content:encoded><![CDATA[肿瘤免疫新靶点：PLA2]]></content:encoded><pubDate>Thu, 01 Apr 2021 09:23:33 +0800</pubDate></item><item><title>索马鲁肽启动NASH三期临床</title><link>https://mp.weixin.qq.com/s/96v3mbqkGiQmpSRpkhVyFA</link><description></description><content:encoded><![CDATA[索马鲁肽启动NASH三期临床]]></content:encoded><pubDate>Wed, 31 Mar 2021 06:50:49 +0800</pubDate></item><item><title>天境生物Claudin 18.2/4-1BB双抗获FDA批准临床</title><link>https://mp.weixin.qq.com/s/jC5WZmTEJcoS6lNcfAdt-g</link><description></description><content:encoded><![CDATA[天境生物Claudin 18.2/4-1BB双抗获FDA批准临床]]></content:encoded><pubDate>Wed, 31 Mar 2021 06:50:49 +0800</pubDate></item><item><title>齐鲁制药免疫毒素Vicineum启动三期临床</title><link>https://mp.weixin.qq.com/s/vc6QdTJUpGJnxiTh8InZCw</link><description></description><content:encoded><![CDATA[齐鲁制药免疫毒素Vicineum启动三期临床]]></content:encoded><pubDate>Wed, 31 Mar 2021 06:50:49 +0800</pubDate></item><item><title>信达生物申报PD-1/TIGIT双抗，国内首个</title><link>https://mp.weixin.qq.com/s/SLYWnMjy0Ao69NhTY_trgA</link><description></description><content:encoded><![CDATA[信达生物申报PD-1/TIGIT双抗，国内首个]]></content:encoded><pubDate>Tue, 30 Mar 2021 07:21:05 +0800</pubDate></item><item><title>信达生物2020营收38亿元，研发费用18亿元</title><link>https://mp.weixin.qq.com/s/9IvkuQWIOjlAok2iz8NCfQ</link><description></description><content:encoded><![CDATA[信达生物2020营收38亿元，研发费用18亿元]]></content:encoded><pubDate>Tue, 30 Mar 2021 07:21:05 +0800</pubDate></item><item><title>天境生物2020营收15亿元，净利润4.7亿元</title><link>https://mp.weixin.qq.com/s/36HVU7CBdzhHZ3P8anHmfw</link><description></description><content:encoded><![CDATA[天境生物2020营收15亿元，净利润4.7亿元]]></content:encoded><pubDate>Tue, 30 Mar 2021 07:21:05 +0800</pubDate></item><item><title>复星/复宏汉霖生物类似药2020销售额8.86亿元</title><link>https://mp.weixin.qq.com/s/PMWdZGk6ICIjvMw0GTWLtw</link><description></description><content:encoded><![CDATA[复星/复宏汉霖生物类似药2020销售额8.86亿元]]></content:encoded><pubDate>Tue, 30 Mar 2021 07:21:05 +0800</pubDate></item><item><title>PD-L1/TGFβ/VEGF：道尔生物、启愈生物、恒瑞医药</title><link>https://mp.weixin.qq.com/s/o6cnSzPY_eyuWGFPV9qKmQ</link><description></description><content:encoded><![CDATA[PD-L1/TGFβ/VEGF：道尔生物、启愈生物、恒瑞医药]]></content:encoded><pubDate>Mon, 29 Mar 2021 10:32:11 +0800</pubDate></item><item><title>M7824之后TGFβ前路何在：整合素αvβ8更具潜力</title><link>https://mp.weixin.qq.com/s/kjZdxXcORgZejgUbQZKkfA</link><description></description><content:encoded><![CDATA[M7824之后TGFβ前路何在：整合素αvβ8更具潜力]]></content:encoded><pubDate>Sun, 28 Mar 2021 08:10:36 +0800</pubDate></item><item><title>永泰生物技术全梳理</title><link>https://mp.weixin.qq.com/s/6qW4s3gg2Dl_ecYkTLurZA</link><description></description><content:encoded><![CDATA[永泰生物技术全梳理]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>Nature：2026年ADC市场规模160亿美元，DS-8201超60亿美元</title><link>https://mp.weixin.qq.com/s/EKiqpjD1jOxKmnjHcgwNJA</link><description></description><content:encoded><![CDATA[Nature：2026年ADC市场规模160亿美元，DS-8201超60亿美元]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item></channel></rss>